Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Off-Label Debate Between FDA, Industry To Formally Begin After Election

Executive Summary

After years of industry prodding, FDA schedules a two-day public meeting in November to establish direction for off-label regulation, but the agency is already being pulled in multiple directions.


Related Content

Off-Label Compendia Weaknesses Illustrated By Tarceva Evidence Gaps
FDA Taps NIH Veteran Corrigan-Curay To Lead Medical Policy Office
Industry's Off-Label Hearing Priorities Taking Shape
Preapproval Safe Harbor Should Extend 18 Months, Payers And Sponsors Say
FDA's Drug Promotion Advisory Reviews Taking Longer
FDA's Off-Label Communication Changes Should Start With Payers – PhRMA
Off-Label Communications: BIO Lays Ethical Foundation For Change
Off-Label Communication Principles From PhRMA, BIO Aim For Reg Changes
Consumer-Focused Off-Label Promotion Seems Possible After Amarin Settlement
US FDA Sets Goal For Biosimilar, Drug Promotion Guidances


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts